MedTrace Logo

Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.

NCT04931537 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-07-20

No results posted yet for this study

Summary

Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.

Conditions

  • Diabetic Nephropathy Type 2
  • Biomarker

Sponsors & Collaborators

  • Second Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Lishui Country People's Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Chao Zheng, MD,PhD · the Second Affiliated Hospital Zhejiang University Schoolof Medicine

  • Yikai Zhang, PhD · the Second Affiliated Hospital Zhejiang University Schoolof Medicine

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04931537 on ClinicalTrials.gov